WEBULL
News
ACOG
6.38
+1.76%
0.11
Weekly Report: what happened at ACOG last week (1222-1226)?
Weekly Report · 16h ago
Weekly Report: what happened at ACOG last week (1215-1219)?
Weekly Report · 12/22 10:22
Alpha Cognition Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 12/19 13:09
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target
Benzinga · 12/19 12:59
Alpha Cognition: Undervalued ZUNVEYL Growth Story Supports Reiterated Buy Rating and $18 Target
TipRanks · 12/19 11:25
Weekly Report: what happened at ACOG last week (1208-1212)?
Weekly Report · 12/15 10:30
Weekly Report: what happened at ACOG last week (1201-1205)?
Weekly Report · 12/08 10:28
Alpha Cognition CEO Joins Titan Partners Virtual Fireside Chat
Reuters · 12/01 22:51
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
Barchart · 12/01 16:51
Weekly Report: what happened at ACOG last week (1124-1128)?
Weekly Report · 12/01 10:23
Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)
TipRanks · 11/24 11:30
Weekly Report: what happened at ACOG last week (1117-1121)?
Weekly Report · 11/24 10:29
Weekly Report: what happened at ACOG last week (1110-1114)?
Weekly Report · 11/17 10:29
Alpha Cognition’s Earnings Call: Strong Sales and Strategic Growth
TipRanks · 11/15 00:35
Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025
Reuters · 11/14 14:47
Alpha Cognition Inc. Reports Q3 2025 Earnings and Strategic Progress
TipRanks · 11/14 04:43
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/13 23:40
Alpha Cognition reports Q3 results
Seeking Alpha · 11/13 21:22
Alpha Cognition Q3 Sales $2.300M Beat $2.033M Estimate
Benzinga · 11/13 21:04
*Alpha Cognition 3Q Loss $1.3M >ACOG
Dow Jones · 11/13 21:01
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.